{"id":"azd9833","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Vaginal dryness"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4650365","moleculeType":"Small molecule","molecularWeight":"476.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AZD9833 functions as a next-generation SERD that achieves rapid and sustained degradation of estrogen receptor alpha in hormone receptor-positive breast cancer cells. Unlike traditional selective estrogen receptor modulators (SERMs), SERDs eliminate the receptor protein entirely rather than simply blocking its activity, preventing both ligand-dependent and ligand-independent signaling. This mechanism overcomes some resistance mechanisms seen with aromatase inhibitors and tamoxifen.","oneSentence":"AZD9833 is an oral selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, blocking estrogen-driven cancer cell growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:13.408Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"},{"name":"Hormone receptor-positive breast cancer in combination with CDK4/6 inhibitors"}]},"trialDetails":[{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":"Advanced Breast Cancer","enrollment":500},{"nctId":"NCT05774951","phase":"PHASE3","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-31","conditions":"Breast Cancer, Early Breast Cancer","enrollment":4300},{"nctId":"NCT06188520","phase":"PHASE1, PHASE2","title":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-05","conditions":"ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)","enrollment":564},{"nctId":"NCT07427394","phase":"PHASE2","title":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-04-10","conditions":"Advanced Breast Cancer","enrollment":24},{"nctId":"NCT04644068","phase":"PHASE1, PHASE2","title":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-12","conditions":"Ovarian Cancer, Breast Cancer, Pancreatic Cancer","enrollment":702},{"nctId":"NCT03616587","phase":"PHASE1","title":"Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-10-11","conditions":"ER+ HER2- Advanced Breast Cancer","enrollment":396},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":315},{"nctId":"NCT04214288","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-04-22","conditions":"Advanced ER-Positive HER2-Negative Breast Cancer","enrollment":240},{"nctId":"NCT04711252","phase":"PHASE3","title":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-01-28","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":1370},{"nctId":"NCT07195227","phase":"PHASE2","title":"Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2025-12-01","conditions":"Hormon Receptor Positive Breast Cancer, Breast Cancer","enrollment":150},{"nctId":"NCT06547164","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-27","conditions":"Healthy Participants","enrollment":40},{"nctId":"NCT04541433","phase":"PHASE1","title":"A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-09-29","conditions":"ER+ HER2- Advanced Breast Cancer","enrollment":10},{"nctId":"NCT05952557","phase":"PHASE3","title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-10-05","conditions":"Breast Cancer, Early Breast Cancer","enrollment":5500},{"nctId":"NCT05790304","phase":"PHASE1","title":"Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-02-20","conditions":"Hepatic Impairment","enrollment":22},{"nctId":"NCT04588298","phase":"PHASE2","title":"A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-11-02","conditions":"HER2-negative Breast Cancer","enrollment":135},{"nctId":"NCT04818632","phase":"PHASE1","title":"AZD9833 China PK Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-11-12","conditions":"ER+, HER2-, Metastatic Breast Cancer","enrollment":28},{"nctId":"NCT05364255","phase":"PHASE1","title":"A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-10","conditions":"ER-positive, HER2-negative Breast Cancer","enrollment":6},{"nctId":"NCT05438303","phase":"PHASE1","title":"Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-06-13","conditions":"Healthy Volunteers","enrollment":59},{"nctId":"NCT05551897","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-04","conditions":"Healthy Subjects","enrollment":14},{"nctId":"NCT04546347","phase":"PHASE1","title":"A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-09-17","conditions":"Healthy Volunteers","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AZD9833","genericName":"AZD9833","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD9833 is an oral selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, blocking estrogen-driven cancer cell growth. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, Hormone receptor-positive breast cancer in combination with CDK4/6 inhibitors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}